Posted by Michael Wonder on 25 Aug 2021
ICER to assess novel agents to prevent chemotherapy-induced neutropenia
25 August 2021 - Report will be subject of CTAF meeting in April 2022; draft scoping document open to public comment until 14 September 2021.
The ICER announced today that it will assess the comparative clinical effectiveness and value of plinabulin (BeyondSpring Pharmaceuticals) and trilaciclib (Cosela, G1 Therapeutics) for the prevention of chemotherapy-induced neutropenia.
